The following is a summary of “Skin Microbiome in the First Year of Life and Its Association With Atopic Dermatitis,” ...

Atopic dermatitis (AD) remains a persistent challenge for pediatric patients, often beginning in infancy and continuing into childhood. “Somewhere between 7, 8, 10% of kids will have episodic and some ...

Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating ...

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). Night-time flare-ups ...

The approval comes at a critical time: approximately 6% of adolescents within this newly approved age group suffer from atopic dermatitis in the UK. In other words, one in five children.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

FDA experts report changes in drug approvals, warnings, and indications for products for use by dermatologists and aesthetic medicine professionals.

INR:3473. india cricket live streaming online Sanofi/Regeneron's Dupixent for the treatment of atopic dermatitis in children ...

atopic dermatitis, and rashes, accounted for 22% of all telemedicine cases, making them the most frequently treated category.

INR:2567. in-play betting Amgen 2019 financial report: 6 new products emerge to take over the biosimilar drugs Sanofi/Regeneron Dupixent successfully treats sever ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

3. Choose appropriate treatments for perioral dermatitis in children and adults, including challenging cases. Perioral dermatitis (POD) is a common facial eruption of women and children ...